DSK Legal advised and assisted OneSource Specialty Pharma Limited with the filing of the Information Memorandum related to the scheme of arrangement involving Strides Pharma Science Limited, Steriscience Specialties Private Limited, and OneSource, for the listing of 11,44,36,021 equity shares of ₹1 each.

DSK Legal team consisted of Avinash Poojari (Associate Partner), Akanksha Dubey (Principal Associate) and Sachi Ray (Associate).

Anand Desai (Managing Partner) acted as the engagement and Relationship Partner.

OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, successfully listed its equity shares on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on January 24, 2025. This milestone followed a Scheme of Arrangement involving Strides Pharma Science Limited and Steriscience Specialties Private Limited, leading to the issuance of 11,44,36,021 equity shares with a face value of ₹1 each. Shareholders of Strides Pharma Science received one equity share of OneSource for every two shares held, while Steriscience Specialties' shareholders were allotted 1,515 equity shares of OneSource for each share they owned

Upon listing, the shares were placed in the 'T' group of securities, indicating that they are settled on a trade-for-trade basis for the initial 10 trading days.

OneSource is a fully integrated, multi-modality specialty pharmaceutical contract development and manufacturing organisation company, focused on developing and manufacturing drug device combinations, biologics, sterile injectables and oral technologies like soft gelatin capsules. 

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.